

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

07 APR 2011

To,


M/S. BIOLOGICAL E. LIMITED
D.NO.18/1 & 3, AZAMABAD
HYDERABAD DIST.

Sub: -Registration of M/S. SHENZHEN HEPALINK PHARMACEUTICAL CO. LTD.21, LANGSHAN ROAD, SONGPINGSHAN, NANSHAN DISTRICT, SHENZHEN P.R.CHINA under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application No. NIL dated 23/02/2011: received by this Office vide diary No : 9663 dated : 01/03/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall conform to the standards / specifications mentioned in the Second Schedule of the Act or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.



सत्यमेव जयते

GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation Ministry of Health & Family Welfare FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India

Under Drugs and Cosmetics Rules, 1945

07 APR 2011

Dated

Registration Certificate No. BD-916


- M/S. SHENZHEN HEPALINK PHARMACEUTICAL CO. LTD. 21, LANGSHAN ROAD, SONGPINGSHAN, NANSHAN DISTRICT, SHENZHEN CITY, GUANDONG PROVINCE P.R.CHINA having factory premises at M/s. SHENZHEN HEPALINK PHARMACEUTICAL CO. LTD. 21, LANGSHAN ROAD, SONGPINGSHAN, NANSHAN DISTRICT, SHENZHEN P.R.CHINA has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
- Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
- This Registration Certificate shall be in force from 01/03/2011 to 28/02/2014 unless it is sooner suspended or cancelled under the rules.
- This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S BIOLOGICAL E. LIMITED D.NO.18/1 & 3, AZAMABAD, HYDERABAD DIST. who will be responsible for the business activities of the manufacturer in India in all respects.
- This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.



Place: New Delhi

Date: 07 APR 2011

LICENSING AUTHORITY
डॉ. सुरेंद्र सिंह
Dr. SURENDR SINGH
औषधि नियंत्रक (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महाविद्यालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002



GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. BD-916
DATED

07 APR 2011

HEPARIN SODIUM IP

OFFICE COPY

CDSCO

CDSCO

ITEMS (ONE) ONLY

सत्यमेव जयते

Place: New Delhi

Date: 07 APR 2011



LICENSING AUTHORITY

डा. सुरिन्द्र सिंह

Dr. SURINDER SINGH Stamp

औषधि नियंत्रक (भारत)/Drugs Controller (India)

स्वास्थ्य सेवा महानिदेशालय

Dt. General of Health Services

FDA Bhawan, Kotla Road,

New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated 07 APR 2011

To,

M/S. BASF INDIA LTD.
BASEMENT OF M/S. SEJPAL PLASTIC PVT
LIMITED C-453, TTC, INDUSTRIAL
AREA, DISTRICT THANE-400705
NEW BOMBAY

Sub: -Registration of M/S. BASF SE CARL-BOSCH-STRASSE 38 67056 LUDWIGSHAFEN, GERMANY under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application No. NIL dated 02/03/2011 received by this Office vide diary No : 10838 dated : 07/03/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall conform to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

GOVERNMENT OF INDIA



Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

सत्यमेव जयते

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. BD-16
DATED 08/08/2008 VALID UPTO 31/12/2011

ENDORSEMENT No. 1

ISOTRETINOIN USP

ITEMS (ONE) ONLY

OFFICE COPY



Place: New Delhi

Date: 07 APR 2011



LICENSING AUTHORITY

डॉ. सुरिन्दर सिंह
Dr. SURINDER SINGH Stamp
औषधि निबंधक (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महाविद्यालय
Dir. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

07 APR 2011

To,

M/S. LIBERTY LIFE SCIENCES
GALA NO. 2, BLDG. NO. 2, 2ND FLOOR,
MANISH COMPOUND, RAHNAL
VILLAGE, THANA-BHIWANDI ROAD,
ANJUR PHATA,
BHIWANDI

Sub: -Registration of M/S. INDUSTRIALE CHIMICA S.r.l, VIA E.H. GRIEG, 13 - 21047 SARONNO (VARESE), ITALY under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application No. NIL dated 06/08/2010: received by this Office vide diary No : 8917 dated : 24/02/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.



सत्यमेव जयते

GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation Ministry of Health & Family Welfare FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India
Under Drugs and Cosmetics Rules, 1945

Registration Certificate No. BD-898

07 APR 2011
Dated

1. M/S. INDUSTRIALE CHIMICA S.r.L., ITLAY having factory premises at M/s. INDUSTRIALE CHIMICA S.r.L., VIA E.H. GRIEG, 13 - 21047 SARONNO (VARESE), ITALY has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s) which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/03/2011 to 28/02/2014 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S LIBERTY LIFE SCIENCES GALA NO. 2, BLDG. NO. 2, 2ND FLOOR, MANISH COMPOUND, RAHNAL VILLAGE, THANA-BHIWANDI ROAD, ANJUR PHATA, BHIWANDI who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date: 07 APR 2011



LICENSING AUTHORITY

डा. सुरेश सिंह

Dr. SURESH SINGH
औद्योगिक नियंत्रक (भारत) / Drugs Controller (India)

स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services

FDA Bhawan, Kotla Road,

New Delhi-110002



सत्यमेव जयते


GOVERNMENT OF INDIA
Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. BD-898
DATED

07 APR 2011

1. LEVONORGESTREL IP
2. DROSPIRENONE USP



Place: New Delhi

Date: 07 APR 2011




LICENSING AUTHORITY

डा. सुरिन्द सिंह
Dr. SURINDER SINGH
के. व. क. (भारत) / Drugs Controller (India)
जनरल सेवा महानिदेशालय
Dir. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

To,

07 APR 2011

M/S. ANANTCO ENTERPRISES PVT LTD.,
CABIN NO. 1 GALA NO. 6 & 7, 194 ARVIND
CHAMABER, GAURI STUDIO COMPOUND
ANDHERI(EAST)
MUMBAI-400069


Sub: -Registration of M/S. ZHUHAI UNITED LABORATORIES CO. LTD. SANZAO SCIENCE & TECHNOLOGY PARK, NATIONAL HI-TECH ZONE, GUANGDONG P.R.CHINA under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

OFFICE COPY

Please refer to your application No. NIL dated 05/03/2011: received by this Office vide diary No : 10575 dated : 07/03/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.



सत्यमेव जयते

GOVERNMENT OF INDIA
Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. BD-395
DATED 03/05/2010 VALID UPTO 30/04/2013

07 APR 2011

ENDORSEMENT No. 1

OFFICE COPY

IMIPENEM AND CILASTATIN SODIUM FOR INJECTION IP
(BULK STERILE)
[IMIPENEM 400mcg/mg & CILASTATIN 400mcg/mg]
BUFFEERED WITH STERILE SODIUM BICARBONATE
200mcg/mg

ITEMS (ONE) ONLY



Place: New Delhi

Date: 07 APR 2011



LICENSING AUTHORITY
डा. सुरिन्द्र सिंह
D: SUPINDER SINGH
औषधि नियंत्रक (संगत) / Drugs Controller (Sangat)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kofa Road,
New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

To,

07 APR 2011

M/S. MEDILINE
UNIT NO. 39, MEZANINE FL NAND
GHANSHYAM IND, EST. OFF MAHAKALI
CAVES RD, ANDHERI(E)
MUMBAI-400093

Sub: -Registration of M/S. SUZHOU HEGNO PHARMACEUTICAL CO.LTD,
DONGXIN VILLAGE LEYU TOWN, ZHANGJIANGANG CITY, JIANGSU PROVICE
215621 CHINA under the Provisions of Drug & Cosmetics Rules for the purpose of
import of drugs in India

OFFICE COPY

Dear Sir,

Please refer to your application No. NIL dated 24/02/2011: received by this Office vide diary No : 9178 dated : 25/02/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.



GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare
FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India

Under Drugs and Cosmetics Rules, 1945

07 APR 2011

Registration Certificate No. BD-912

Dated

1. M/S. SUZHOU HEGNO PHARMACEUTICAL CO.LTD, DONGXIN VILLAGE LEYU TOWN, ZHANGJIANGANG CITY, JIANGSU PROVINCE 215621 CHINA having factory premises at M/s. SUZHOU HEGNO PHARMACEUTICAL CO.LTD, DONGXIN VILLAGE LEYU TOWN, ZHANGJIANGANG CITY, JIANGSU PROVINCE 215621 CHINA has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/03/2011 to 28/02/2014 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S MEDILINE UNIT NO. 39, MEZANINE FL NAND GHANSHYAM IND, EST. OFF MAHAKALI CAVES RD, ANDHERI(E), MUMBAI-400093 who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.




Place: New Delhi

Date: 07 APR 2011

LICENSING AUTHORITY

डा. सुरिंदर सिंह
Dr. SURINDER SINGH
औद्योगिक नियंत्रक (भारत)/Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002



सत्यमेव जयते


GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. BD-912
DATED 07 APR 2011


VITAMIN B6 (PYRIDOXINE HCl) IP



Place: New Delhi

Date: 07 APR 2011




LICENSING AUTHORITY
डा. सुरिन्द्र सिंह
Dr. SURINDER SINGH Seal/Stamp
औषधि नियंत्रक (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

To,

M/S. ZAMBON (INDIA) PVT. LTD.
J.M.D. REGENT SQUARE, SUIT NO, 301,
3RD FLOOR, MAIN MEHRAULI
GURGAON ROAD,
GURGAON

Sub: -Registration of M/S. ZAMBON SWITZERLAND LTD.VIA INDUSTRIA, 13-CH-6814, CADEMPINO SWITZERLAND under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application No. NIL dated 10/02/2011: received by this Office vide diary No : 6845 dated : 11/02/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall conform to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.



सत्यमेव जयते

GOVERNMENT OF INDIA
Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare
FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India
Under Drugs and Cosmetics Rules, 1945

Registration Certificate No. FF-572

07 APR 2011
Date

1. M/S. ZAMBON SWITZERLAND LTD. VIA INDUSTRIA, 13-CH-6814, CADEMPINO SWITZERLAND having factory premises at M/s. ZAMBON SWITZERLAND LTD. VIA INDUSTRIA, 13-CH-6814, CADEMPINO SWITZERLAND has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/03/2011 to 28/02/2014 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S ZAMBON (INDIA) PVT. LTD. I.M.D. REGENT SQUARE, SUIT NO, 301, 3RD FLOOR, MAIN MEHRAULI GURGAON ROAD,, GURGAON who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date:

07 APR 2011



LICENSING AUTHORITY

डा. सुरिन्द सिंह
Dr. SURINDER SINGH
औद्योगिक निरीक्षण (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi: 110002



GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)


NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. FF-572
DATED 07 APR 2011

*FOSFOMYCIN TROMETAMOL SACHETS

EACH SACHET CONTAINS:

FOSFOMYCIN TROMETAMOL ... 5.631 GM
EQUIVALENT TO FOSFOMYCIN ... 3GM

OFFICE COPY



ITEMS (ONE) ONLY

*COPY OF PERMISSION OF RULE 122A SHALL BE SUBMITTED AT TIME OF
APPLICATION OF FORM 10.

Place: New Delhi

Date: 07 APR 2011



LICENSING AUTHORITY

डा. सुरिन्द्र सिंह
Dr. SURINDER SINGH / Stamp
औषधि नियंत्रक (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

To,

07 APR 2011

M/S. DPB ANTIBIOTICS
HISSA NO. 4 & 5, H. NO. 472, OFFICE NO.
19, C/O. GANESH CORPORATION,
KHANDAGLE ESTATE, PURNA VILLAGE,
BHIVANDI


~~Sub: -Registration of M/S. ZHEJIANG APELOA TOSPO PHARMACEUTICAL CO. LTD. NO. 499 JIANGNAN ROAD, HENGDIAN INDUSTRIAL ZONE DONGYANG CITY ZHEJIANG PROVINCE CHINA under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India~~

Dear Sir,

OFFICE COPY

Please refer to your application No. NIL dated 18/02/2011: received by this Office vide diary No : 8203 dated : 21/02/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall conform to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.



GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare
FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India
Under Drugs and Cosmetics Rules, 1945

07 APR 2011

Registration Certificate No. BD-909

Dated

- M/S. ZHEJIANG APELOA TOSPO PHARMACEUTICAL CO. LTD. NO. 499 JIANGNAN ROAD, HENGDIAN INDUSTRIAL ZONE DONGYANG CITY ZHEJIANG PROVINCE CHINA having factory premises at M/s. ZHEJIANG APELOA TOSPO PHARMACEUTICAL CO. LTD. NO. 499 JIANGNAN ROAD, HENGDIAN INDUSTRIAL ZONE DONGYANG CITY ZHEJIANG PROVINCE CHINA has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
- Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
- This Registration Certificate shall be in force from 01/03/2011 to 28/02/2014 unless it is sooner suspended or cancelled under the rules.
- This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S DPB ANTIBIOTICS HISSA NO. 4 & 5, H. NO. 472, OFFICE NO. 19, C/O. GANESH CORPORATION, KHANDAGLE ESTATE, PURNA VILLAGE, BHIVANDI who will be responsible for the business activities of the manufacturer in India in all respects.
- This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

OFFICE COPY



Place: New Delhi

Date: 07 APR 2011

Surinder Singh

LICENSING AUTHORITY
SURINDER SINGH
Secretary
Ministry of Health & Family Welfare
FDA Bhawan, Kotla Road,
New Delhi-110002




GOVERNMENT OF INDIA
 Central Drugs Standard Control Organisation
 Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
 UNDER REGISTRATION CERTIFICATE NO. BD-909
 DATED

07 APR 2011

CEFIXIME IP



ITEMS (ONE) ONLY

सत्यमेव जयते

Place: New Delhi

Date: 7 APR 2011



LICENSING AUTHORITY

डा. सुरिन्दर सिंह
 Dr. SURINDER SINGH
 औषधि नियंत्रक (भारत) / Drugs Controller (India)
 स्वास्थ्य सेवा महानिदेशालय
 Dte. General of Health Services
 FDA Bhawan, Kotla Road,
 New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

07 APR 2011

To,


M/S. URSAPHARM INDIA PRIVATE LTD.
F-193, 628, G.F. VILLAGE LADO SARAI,
NEW DELHI-110030

Sub: -Registration of M/S. URSAPHARM, ARZNEIMITTEL GMBH, INUSTRIESTRABE 35, 66129 SAARBRUCKEN, GERMANY under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application No. NIL dated 29/12/2010: received by this Office vide diary No : 2130 dated : 14/01/2011 on the above subject/Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.



सत्यमेव जयते

GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India

Under Drugs and Cosmetics Rules, 1945

07 APR 2011

Registration Certificate No. FF-421

Dated


- M/S. URSAPHARM, ARZNEIMITTEL GMBH, INUSTRIESTRABE 35, 66129 SAARBRUCKEN, GERMANY having factory premises at M/s. URSAPHARM, ARZNEIMITTEL GMBH, INUSTRIESTRABE 35, 66129 SAARBRUCKEN, GERMANY has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
- Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
- This Registration Certificate shall be in force from 01/06/2010 to 31/05/2013 unless it is sooner suspended or cancelled under the rules.
- This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S URSAPHARM INDIA PRIVATE LTD. F-193, 628, G.F. VILLAGE LADO SARAI, NEW DELHI-110030 who will be responsible for the business activities of the manufacturer in India in all respects.
- This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.



Place: New Delhi

Date: 07 APR 2011

LICENSING AUTHORITY
Dr. SURINDER SINGH
औषधि नियंत्रक (असुर) Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002



सत्यमेव जयते

GOVERNMENT OF INDIA


Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. FF-421
DATED 07 APR 2011

1. POVIDONE 20.00 MG/ML EYE DROPS

2. XYLOMETAZOLINE HYDROCHLORIDE NASAL SPRAY
SOLUTION(1.00MG/ML)



ITEMS (TWO) ONLY

सत्यमेव जयते

Place: New Delhi

Date:

07 APR 2011



LICENSING AUTHORITY

डा. सुरिन्द्र सिंह

Dr. SURINDER SINGH Seal/Stamp

जौषधि नियंत्रक (भारत)/Drugs Controller (India)

स्वास्थ्य सेवा महानिदेशालय

Dte. General of Health Services

FDA Bhawan, Kotla Road,

New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

To,

07 APR 2011

M/S. BASF INDIA LTD.
BASEMENT OF M/S. SEJPAL PLASTIC PVT
LIMITED C-453, TTC, INDUSTRIAL
AREA, DISTRICT THANE -400705
NEW BOMBAY

Sub: -Registration of M/S. BASF PHARMA CHEMIKALIEN GMBH & CO. KG, PLANT MINDEN, KARLSTRABE, 15-39, 42-44, 32423 MINDEN, FEDERAL REPUBLIC OF GERMANY under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application No. NIL dated 08/02/2011: received by this Office vide diary No : 7258 dated : 15/02/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall conform to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

OFFICE COPY

GOVERNMENT OF INDIA



Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

सत्यमेव जयते


NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. BD-13
DATED 30/12/2008 VALID UPTO 31/12/2011

07 APR 2011

ENDORSEMENT No. 1

PHENYLEPHRINE HYDROCHLORIDE IP

ITEMS (ONE) ONLY



Place: New Delhi

Date: 07 APR 2011



LICENSING AUTHORITY

डा. सुरिन्द्र सिंह / Stamp
Dr. SURINDER SINGH
औषधि नियंत्रक (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002